ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ALX Oncology Holdings (Nasdaq: ALXO), a clinical-stage biotechnology company focused on developing immune system-boosting cancer therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Jason Lettmann will present a company overview on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time.
The presentation will be accessible via live webcast through a direct link and the Investors section of ALX Oncology's website under the Events section of the News and Events tab. A replay of the presentation will remain available for up to 30 days after the event.
ALX Oncology Holdings (Nasdaq: ALXO), una compagnia biotecnologica in fase clinica che si concentra sullo sviluppo di terapie contro il cancro che potenziano il sistema immunitario, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare a San Francisco. Il CEO Jason Lettmann presenterà una panoramica dell'azienda mercoledì 15 gennaio 2025, alle 15:00 ora del Pacifico.
La presentazione sarà accessibile tramite webcast dal vivo attraverso un link diretto e la sezione Investitori del sito web di ALX Oncology, sotto la sezione Eventi della scheda News ed Eventi. Una registrazione della presentazione sarà disponibile per un massimo di 30 giorni dopo l'evento.
ALX Oncology Holdings (Nasdaq: ALXO), una compañía de biotecnología en etapa clínica centrada en desarrollar terapias contra el cáncer que refuerzan el sistema inmunológico, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan en San Francisco. El CEO Jason Lettmann presentará una visión general de la empresa el miércoles 15 de enero de 2025, a las 3:00 p.m. Hora del Pacífico.
La presentación se podrá acceder a través de una transmisión en vivo mediante un enlace directo y la sección de Inversores del sitio web de ALX Oncology bajo la sección de Eventos de la pestaña de Noticias y Eventos. Una repetición de la presentación estará disponible durante un máximo de 30 días después del evento.
ALX Oncology Holdings (Nasdaq: ALXO)는 면역 체계를 강화하는 암 치료제를 개발하는 임상 단계의 생명공학 회사로, 샌프란시스코에서 열리는 제43회 JP 모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다. CEO 제이슨 레트먼은 2025년 1월 15일 수요일 오후 3시 태평양 표준시에 회사 개요를 발표할 예정입니다.
발표는 ALX Oncology 웹사이트의 뉴스 및 이벤트 탭의 이벤트 섹션 아래 투자자 섹션을 통해 직접 링크와 함께 실시간 웹캐스트로 접근할 수 있습니다. 발표는 행사 후 최대 30일까지 다시 볼 수 있습니다.
ALX Oncology Holdings (Nasdaq: ALXO), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies contre le cancer renforçant le système immunitaire, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare à San Francisco. Le PDG Jason Lettmann présentera un aperçu de l'entreprise le mercredi 15 janvier 2025 à 15h00, heure du Pacifique.
La présentation sera accessible par webcast en direct via un lien direct et la section Investisseurs du site Web d'ALX Oncology, sous la section Événements de l'onglet Actualités et Événements. Un enregistrement de la présentation sera disponible pendant 30 jours après l'événement.
ALX Oncology Holdings (Nasdaq: ALXO), ein biomedizinisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien zur Stärkung des Immunsystems gegen Krebs konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz in San Francisco bekannt gegeben. CEO Jason Lettmann wird am Mittwoch, den 15. Januar 2025, um 15:00 Uhr pazifischer Zeit einen Unternehmensüberblick präsentieren.
Die Präsentation wird live über einen direkten Link und den Investorenbereich der ALX Oncology-Website im Bereich Veranstaltungen unter dem Tab Nachrichten und Veranstaltungen zugänglich sein. Eine Wiederholung der Präsentation wird bis zu 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer, Jason Lettmann, will deliver a company overview presentation on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time.
A live webcast of the presentation is available by clicking the link and can also be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the News and Events tab. A replay of the webcast will be archived for up to 30 days following the presentation date.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
FAQ
When is ALX Oncology (ALXO) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch ALX Oncology's J.P. Morgan Healthcare Conference presentation?
How long will the replay of ALXO's J.P. Morgan Healthcare Conference presentation be available?
What is the focus of ALX Oncology's presentation at the 2025 J.P. Morgan Healthcare Conference?
